Schering misjudges Claritin inventory
Executive Summary
Schering-Plough is reducing its fourth quarter earnings estimate by about $250 mil. (16-18 cents per share) because of "a more-rapid-than-anticipated decline in U.S. prescriptions for Claritin" following the OTC launch in December. Schering says it will not record any sales on shipments of Rx product to wholesalers until an actual prescription is dispensed...
You may also be interested in...
Schering Inventory Reductions Cause Drop In Intron, Temodar, Nasonex Sales
Schering-Plough's poor first quarter results reflect inventory buildup issues beyond Rx Claritin
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.